Study 200170: A Rollover Study to Provide Continued Treatment With Eltrombopag
Phase of Trial: Phase IV
Latest Information Update: 14 Feb 2019
Price : $35 *
At a glance
- Drugs Eltrombopag (Primary)
- Indications Thrombocytopenia
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis Pharmaceuticals
- 04 Feb 2019 Status changed from active, no longer recruiting to recruiting.
- 12 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Aug 2016 Planned End Date changed from 1 Dec 2023 to 1 Jan 2024.